Jubilant Pharmova : Press Release

	December 14, 2022
BSE Limited	National Stock Exchange of India Limited
Floor 25, P. J. Towers	Exchange Plaza
Dalal Street, Fort	Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001	Mumbai - 400 051
Scrip Code: 530019	Symbol: JUBLPHARMA
Dear Sirs,

We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to take the same on record.

Thanking you,

Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor

Digitally signed by Naresh Kapoor

Date: 2022.12.14 14:30:57 +05'30'

Naresh Kapoor Company Secretary

Encl.: as above

	Jubilant Pharmova Limited
	1A, Sector 16A, Noida - 201301, India
	Tel.: [phone]
PRESS RELEASE	www.jubilantpharmova.com
Noida, Wednesday, December 14, 2022

Jubilant Pharmova announces USFDA completes inspection of its

API Manufacturing Facility at Nanjangud, India

Jubilant Pharmova Limited today announced that the United States Food and Drug Administration (USFDA) has concluded inspection of the Active Pharmaceutical Ingredients (API) manufacturing facility at Nanjangud on December 13, 2022.

The US FDA has issued eight observations pursuant to the completion of the inspection. The company will submit an action plan on the observations and will engage with US FDA for next steps.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Specialty Pharmaceuticals, Contract Research, Development and Manufacturing (CRDMO), CDMO, Generics and Proprietary Novel Drugs businesses. Specialty Pharmaceuticals, CDMO and Generics businesses through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of radio- pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics/branded formulations through five manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Pharmova Limited is also involved in manufacturing of Active Pharmaceutical Ingredients (API) from its USFDA approved facility in Nanjangud, India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto- immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

For more information, please contact:

For Investors

Surajit Pal

Ph: [phone]

E-mail: [e-mail]

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the

anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.